Hormonal regulation of nitric oxide (NO) in cardio-metabolic diseases

Current Pharmaceutical Design

Volumn 23, Issue 10, 2017, Pages 1427-1434

  Sudar Milovanovic, Emina ^a   Zafirovic, Sonja ^a   Jovanovic, Aleksandra ^a   Trebaljevac, Jovana ^a   Obradovic, Milan ^a   Cenic Milosevic, Desanka ^b   Isenovic, Esma R ^a,b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY BUSINESS ACADEMY   (Serbia)

Author keywords

Cardio metabolic risk; Estradiol; Insulin like growth factor 1; Nitric oxide; Nitric oxide synthase

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ESTRADIOL; ESTROGEN RECEPTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; NITRIC OXIDE SYNTHASE;

ATHEROSCLEROSIS; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HORMONAL REGULATION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LEUKOCYTE ADHERENCE; METABOLIC DISORDER; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE CELL; VASODILATATION; ANIMAL; METABOLISM;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; METABOLIC DISEASES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

EID: 85017480199     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612823666170124124855     Document Type: Review

References (156)

1. Sudar E, Zafirovic S, Dobutovic B, et al. Obesity as a risk factor for cardiovascular diseases: one of the biggest problems in health care today. Life Safety Security 2013; 1: 1-7.
2. Lu M, Yang CB, Gao L, Zhao JJ. Mechanism of subclinical hypothyroidism accelerating endothelial dysfunction (Review). Exp Ther Med 2015; 9: 3-10.
3. Sudar E, Dobutovic B, Soskic S, et al. Regulation of inducible nitric oxide synthase activity/expression in rat hearts from ghrelintreated rats. J Physiol Biochem 2011; 67: 195-4.
4. Stojiljkovic M, Zakula Z, Koricanac G, et al. Regulation of cardiac nitric oxide synthase in acute type I diabetes: Modulation of Larginine availability and arginase activity. Adv Sci Lett 2012; 5: 566-74.
5. Isenovic E, Soskic S, Dungen HD, et al. Regulation of endothelial nitric oxide synthase in pathophysiological conditions. Cardiovas Hematol Disorders Drug Targets 2011; 11(2): 109-18.
6. Hingorani A D. Polymorphisms in endothelial nitric oxide synthase and atherogenesis: John French Lecture 2000. Atherosclerosis 2001; 154: 521-7.
7. Chatsuriyawong S, Gozal D, Kheirandish-Gozal L, et al. Genetic variance in nitric oxide synthase and endothelin genes among children with and without endothelial dysfunction. J Trans Med 2013; 11: 227.
8. Morrell CN. Reactive oxygen species: Finding the right balance. Circ Res 2008; 103: 571-2.
9. Brand S, Amann K, Schupp N. Angiotensin II-induced hypertension dose-dependently leads to oxidative stress and DNA damage in mouse kidneys and hearts. J Hypertens 2013; 31: 333-44.
10. Isenovic E R, Divald A, Milivojevic N, et al. Interactive effects of insulin-like growth factor-1 and beta-estradiol on endothelial nitric oxide synthase activity in rat aortic endothelial cells. Metabolism 2003; 52: 482-7.
11. Isenovic ER, Meng Y, Divald A, Milivojevic N, Sowers JR. Role of phosphatidylinositol 3-kinase/Akt pathway in angiotensin II and insulin-like growth factor-1 modulation of nitric oxide synthase in vascular smooth muscle cells. Endocrine 2002; 19: 287-92.
12. Stanimirovic J, Obradovic M, Jovanovic A, et al. A high fat diet induces sex-specific differences in hepatic lipid metabolism and nitrite/ nitrate in rats. Nitric oxide: Biol Chem 2016; 54: 51-9.
13. Sudar Milovanovic E, Jovanovic A, Misirkic-Marjanovic M, et al. Effects of intracerebroventricularly (ICV) injected ghrelin on cardiac inducible nitric oxide synthase activity/expression in obese rats. Exp Clin Endocrinol Diabetes 2015; 123: 581-8.
14. Obradovic M, Gluvic Z, Sudar-Milovanovic E, et al. Nitric oxide as a marker for levo-thyroxine therapy in subclinical hypothyroid patients. Curr Vascular Pharmacol 2016; 14: 266-70.
15. Cohen RA. The potential clinical impact of 20 years of nitric oxide research. Am J Physiol 1999; 276: H1404-7.
16. Kirkham P, Rahman I. Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy. Pharmacol Ther 2006; 111: 476-94.
17. Li H, Forstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol 2000; 190: 244-54.
18. Mungrue IN, Bredt DS, Stewart DJ, Husain M. From molecules to mammals: what's NOS got to do with it? Acta Physiol Scandinavica 2003; 179: 123-35.
19. Mayer B, Hemmens B. Biosynthesis and action of nitric oxide in mammalian cells. Trends Biochem Sci 1997; 22: 477-81.
20. Zhang P, Xu X, Hu X, et al. Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure. Circ Res 2007; 100: 1089-98.
21. Forstermann U, Li H, Schwarz PHK. Signal transduction by reactive oxygen and nitrogen species. 1st ed. Netherlands: Kluwer Academic Publishers; 2004.
22. Sudar-Milovanovic E, Obradovic M, Jovanovic A, et al. Benefits of L-arginine on cardiovascular system. Mini Rev Med Chem 2015; 16: 94-103.
23. Gibson T. Hyperuricemia, gout and the kidney. Curr Opin Rheumatol 2012; 24: 127-31.
24. Khazan M, Hdayati M. The role of nitric oxide in health and diseases. Scimetr 2015; 3: e20987.
25. Bian K, Doursout M F, Murad F. Vascular system: role of nitric oxide in cardiovascular diseases. J Clin Hypertension 2008; 10: 304-10.
26. Forstermann U, Sessa W C. Nitric oxide synthases: regulation and function. Eur Heart J 2012; 33: 829-37, 37a-37d.
27. Noronha BT, Li JM, Wheatcroft SB, Shah AM, Kearney MT. Inducible nitric oxide synthase has divergent effects on vascular and metabolic function in obesity. Diabetes 2005; 54: 1082-9.
28. Naseem KM. The role of nitric oxide in cardiovascular diseases. Mol Aspects Med 2005; 26: 33-65.
29. Napoli C, Ignarro LJ. Nitric oxide and pathogenic mechanisms involved in the evelopment of vascular diseases. Pharm Res 2009; 32: 1103-8.
30. Zago AS, Zanesco A. Nitric oxide, cardiovascular disease and physical exercise. 2006; 87: e264-70.
31. Giles T D. Aspects of nitric oxide in health and disease: a focus on hypertension and cardiovascular disease. J Clin Hypertens 2006; 8: 2-16.
32. Kapakos G, Bouallegue A, Daou GB, Srivastava AK. Modulatory role of nitric Oxide/cGMP system in endothelin-1-induced signaling responses in vascular smooth muscle cells. Curr Cardiol Rev 2010; 6: 247-54.
33. Chatsuriyawong S, Gozal D, Kheirandish-Gozal L, et al. Genetic variance in nitric oxide synthase and endothelin genes among children with and without endothelial dysfunction. J Trans Med 2013; 11: 227.
34. Kugiyama K, Yasue H, Okumura K, et al. Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation 1996; 94: 266-71.
35. Sarkar R, Webb RC. Does nitric oxide regulate smooth muscle cell proliferation? A critical appraisal. Res JV, editor1998. 135-42 p.
36. Kypreos KE, Zafirovic S, Petropoulou PI, et al. Regulation of endothelial nitric oxide synthase and high-density lipoprotein quality by estradiol in cardiovascular pathology. J cardiovas pharmacol ther 2014; 19: 256-68.
37. Liu VW, Huang PL. Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthase gene disrupted mice. Cardiovascular Res 2008; 77: 19-29.
38. Dobutovic B, Smiljanic K, Soskic S, Düngen HD, E.R. I. Nitric oxide and its role in cardiovascular diseases. Open Nitric Oxide J 2011; 3: 65-71.
39. Andrew PJ, Mayer B. Enzymatic function of nitric oxide synthases. Cardiovas Res 1999; 43: 521-31.
40. Mayer B, Schrammel A, Klatt P, Koesling D, Schmidt K. Peroxynitrite-induced accumulation of cyclic GMP in endothelial cells and stimulation of purified soluble guanylyl cyclase. Dependence on glutathione and possible role of S-nitrosation. J Biol Chem 1995; 270: 17355-60.
41. Hobbs AJ. Soluble guanylate cyclase: the forgotten sibling. Trends Pharmacol Sci 1997; 18: 484-91.
42. Soskic SS, Dobutovic BD, Sudar EM, et al. Regulation of inducible nitric oxide synthase (iNOS) and its potential role in insulin resistance, diabetes and heart failure. Open Cardiovas Med J 2011; 5: 153-63.
43. Ignarro LJ, Buga GM, Byrns RE, Wood KS, Chaudhuri G. Endothelium-derived relaxing factor and nitric oxide possess identical pharmacologic properties as relaxants of bovine arterial and venous smooth muscle. J Pharmacol Exp Ther 1988; 246: 218-26.
44. Yan Q, Yokota T, Zhang W, GK H. Expression of inducible nitric oxide synthase inhibits platelet adhesion and restores blood flow in the injured artery. Circ Res 1996; 79: 38-44.
45. Sylman JL, Lantvit SM, Reynolds MM, Neeves KB. The relative role of soluble guanylyl cylase dependent and independent pathways in nitric oxide inhibition of platelet aggregation under flow. Cell Mol Bioeng 2014; 7: 421-31.
46. Homer KL, Wanstall JC. Cyclic GMP-independent relaxation of rat pulmonary artery by spermine NONOate, a diazeniumdiolate nitric oxide donor. Br J Pharmacol 2000; 131: 673-82.
47. Jia YX, Pan CS, Yang JH, et al. Altered L-arginine/nitric oxide synthase/nitric oxide pathway in the vascular adventitia of rats with sepsis. Clin Exp Pharmacol Physiol 2006; 33: 1202-8.
48. Tapiero H, Mathe G, Couvreur P, Tew KD. I. Arginine. Biomed Pharmacother 2002; 56: 439-45.
49. Ash DE. Structure and function of arginases. J Nutr 2004; 134: 2760S-4S; discussion 5S-7S.
50. Wu G. Synthesis of citrulline and arginine from proline in enterocytes of postnatal pigs. Am J Physiol 1997: G1382-90.
51. Berkowitz DE, White R, Li D, et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 2003; 108: 2000-6.
52. Chicoine LG, Paffett ML, Young TL, Nelin LD. Arginase inhibition increases nitric oxide production in bovine pulmonary arterial endothelial cells. Am J Physiol Lung Cell Mol Physiol 2004; 287(1): L60-8.
53. Nikolic D, Katsiki N, Montalto G, et al. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients 2013; 5: 928-48.
54. Visek WJ. Arginine needs, physiological state and usual diets. A reevaluation. J Nutr 1986; 116: 36-46.
55. Rath M, Müller I, Kropf P, Closs EI, Munder M. Metabolism via arginase or nitric oxide synthase: Two competing arginine pathways in macrophages. Front Immunol 2014; 5: 532.
56. Schulz R, Rassaf T, Massion PB, Kelm M, Balligand JL. Recent advances in the understanding of the role of nitric oxide in cardiovascular homeostasis. Pharmacol Ther 2005; 108: 225-56.
57. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regulatory, Integrative Comp Physiol 2003; 284: R1-12.
58. Xia Y, Dawson VL, Dawson TM, Snyder SH, Zweier JL. Nitric oxide synthase generates superoxide and nitric oxide in argininedepleted cells leading to peroxynitrite-mediated cellular injury. Proc Natl Acad Sci USA 1996; 93: 6770-4.
59. Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem 2003; 278: 22546-54.
60. Takimoto E, Champion HC, Li M, et al. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest 2005; 115: 1221-31.
61. Massion PB, Balligand JL. Relevance of nitric oxide for myocardial remodeling. Curr Heart Failure Rep 2007; 4: 18-25.
62. Umar S, van der Laarse A. Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem 2010; 333: 191.
63. Drexler H, Kastner S, Strobel A, et al. Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. J Am College Cardiol 1998; 32: 955-63.
64. Damy T, Ratajczak P, Shah AM, et al. Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet 2004; 363: 1365-7.
65. Hickner RC, Kemeny G, Stallings HW, Manning SM, McIver KL. Relationship between body composition and skeletal muscle eNOS. Int J Obesit 2006; 30: 308-12.
66. Imrie H, Abbas A, Viswambharan H, et al. Vascular insulin-like growth factor-I resistance and diet-induced obesity. Endocrinology 2009; 150: 4575-82.
67. Jonk AM, Houben AJ, de Jongh RT, et al. Microvascular dysfunction in obesity: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Physiology 2007; 22: 252-60.
68. Roberts CK, Barnard RJ, Sindhu RK, et al. A high-fat, refinedcarbohydrate diet induces endothelial dysfunction and oxidant/ antioxidant imbalance and depresses NOS protein expression. J Appl Physiol 2005; 98: 203-10.
69. Balligand JL, Cannon PJ. Nitric oxide synthases and cardiac muscle. Autocrine and paracrine influences. Arterioscler Thromb Vasc Biol 1997; 17: 1846-58.
70. Nathan C. Inducible nitric oxide synthase: what difference does it make? J Clin Invest 1997; 100: 2417-23.
71. Nathan C, Xie Q W. Regulation of biosynthesis of nitric oxide. J Biol Chem 1994; 269: 13725-8.
72. LaPointe MC, Isenovic E. Interleukin-1beta regulation of inducible nitric oxide synthase and cyclooxygenase-2 involves the p42/44 and p38 MAPK signaling pathways in cardiac myocytes. Hypertension 1999; 33: 276-82.
73. Fukuchi M, Hussain SN, Giaid A. Heterogeneous expression and activity of endothelial and inducible nitric oxide synthases in endstage human heart failure: their relation to lesion site and betaadrenergic receptor therapy. Circulation 1998; 98: 132-9.
74. Vejlstrup NG, Bouloumie A, Boesgaard S, et al. Inducible nitric oxide synthase (iNOS) in the human heart: expression and localization in congestive heart failure. J Mol And Cell Cardiol 1998; 30: 1215-23.
75. Petruson K, Stalfors J, Jacobsson KE, Ny L, Petruson B. Nitric oxide production in the sphenoidal sinus by the inducible and constitutive isozymes of nitric oxide synthase. Rhinology 2005; 43: 18-23.
76. Alderton W K, Cooper C E, Knowles R G. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001; 357: 593-615.
77. Chen Y, Traverse JH, Du R, Hou M, Bache RJ. Nitric oxide modulates myocardial oxygen consumption in the failing heart. Circulation 2002; 106: 273-9.
78. Gealekman O, Abassi Z, Rubinstein I, Winaver J, Binah O. Role of myocardial inducible nitric oxide synthase in contractile dysfunction and beta-adrenergic hyporesponsiveness in rats with experimental volume-overload heart failure. Circulation 2002; 105: 236-43.
79. Haywood GA. Expression of inducible nitric oxide synthase in human heart failure. Circulation 1996; 93: 1 087-94.
80. Razavi HM, Hamilton JA, Feng Q. Modulation of apoptosis by nitric oxide: implications in myocardial ischemia and heart failure. Pharmacol Ther 2005; 106: 147-62.
81. Guo Y, Jones WK, Xuan YT, et al. The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci USA 1999; 96: 11507-12.
82. Lowenstein CJ. NO news is good news. Proc Natl Acad Sci USA 1999; 96: 10953-4.
83. Maulik N, Sato M, Price BD, Das DK. An essential role of NFkappaB in tyrosine kinase signaling of p38 MAP kinase regulation of myocardial adaptation to ischemia. FEBS Lett 1998; 429: 365-9.
84. Melino G, Bernassola F, Knight RA, et al. S-nitrosylation regulates apoptosis. Nature 1997; 388: 432-3.
85. Furchgott RF, Cherry PD, Zawadzki JV, Jothianandan D. Endothelial cells as mediators of vasodilation of arteries. J Cardiovas Pharmacol 1984; 6 Suppl 2: S336-43.
86. Haywood G, Tsao PS, von der Leyen HE, et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation 1996; 93: 1087-94.
87. Drexler H, Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol 1999; 31: 51-60.
88. de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett 2008; 582: 97-5.
89. Perreault M, Marette A. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat med 2001; 7: 1138-43.
90. Barros RP, Machado UF, Warner M, Gustafsson JA. Muscle GLUT4 regulation by estrogen receptors ERbeta and ERalpha. Proc Natl Acad Sci USA 2006; 103: 1605-8.
91. Resanovic I, Rizzo M, Zafirovic S, et al. Anti-atherogenic effects of 17beta-estradiol. Horm Metabol Res 2013; 45: 701-8.
92. Simpson ER, Misso M, Hewitt KN, et al. Estrogen--the good, the bad, and the unexpected. Endocrine Rev 2005; 26: 322-30.
93. Smiley DA, Khalil RA. Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vessels. Curr Med Chem 2009; 16: 1863-87.
94. Masood DE, Roach EC, Beauregard KG, Khalil RA. Impact of sex hormone metabolism on the vascular effects of menopausal hor mone therapy in cardiovascular disease. Curr Drug Metabol 2010; 11: 693-14.
95. Marino M, Galluzzo P, Ascenzi P. Estrogen signaling multiple pathways to impact gene transcription. Curr Genom 2006; 7: 497-8.
96. Rogachefsky RA, Mendelsohn RB. Intraoperative use of an external fixator distraction device for corrective distal radius osteotomy. Tech Hand Up Extrem Surg 1999; 3: 203-9.
97. Russell KS, Haynes MP, Sinha D, Clerisme E, Bender JR. Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc Natl Acad Sci USA 2000; 97: 5930-5.
98. Obradovic M, Sudar E, Zafirovic S, et al. Estradiol in vivo induces changes in cardiomyocytes size in obese rats. Angiology 2015; 66: 25-35.
99. Koricanac G, Tepavcevic S, Zakula Z, et al. Interference between insulin and estradiol signaling pathways in the regulation of cardiac eNOS and Na(+)/K(+)-ATPase. Eur J Pharmacol 2011; 655: 23-30.
100. Sitaramayya A. Signal transduction: pathways, mechanisms and diseases. Zhang D, editor. Berlin Heidelberg: Springer-Verlag 2009.
101. Thomas P, Alyea R, Pang Y, et al. Conserved estrogen binding and signaling functions of the G protein-coupled estrogen receptor 1 (GPER) in mammals and fish. Steroids 2010; 75: 595-602.
102. Meyer MR, Prossnitz ER, Barton M. GPER/GPR30 and regulation of vascular tone and blood pressure. Immunol Endocr Metab Agents Med Chem 2011; 11: 255-61.
103. Orshal JM, Khalil RA. Gender, sex hormones, and vascular tone. Am J Physiol Regulatory, Integrative Comparative Physiol 2004; 286: R233-49.
104. + channels in coronary vasodilation induced by 17betaestradiol in ischemic heart failure. FASEB J 1997; 11: 793-9.
105. Lin J, Steenbergen C, Murphy E, Sun J. Estrogen receptor-beta activation results in S-nitrosylation of proteins involved in cardioprotection. Circulation 2009; 120: 245-54.
106. 2+ loading and adrenergic stimulation reveal male/female differences in susceptibility to ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2002; 283: H481-9.
107. Kan WH, Hsu JT, Ba ZF, et al. p38 MAPK-dependent eNOS upregulation is critical for 17beta-estradiol-mediated cardioprotection following trauma-hemorrhage. Am J Physiol Heart Circ Physiol 2008; 294: H2627-36.
108. Nevzati E, Shafighi M, Bakhtian KD, et al. Estrogen induces nitric oxide production via nitric oxide synthase activation in endothelial cells. Acta Neurochirurgica Suppl 2015; 120: 141-5.
109. Simoncini T, Hafezi-Moghadam A, Brazil D P, et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000; 407: 538-41.
110. Qiao X, McConnell KR, Khalil RA. Sex steroids and vascular responses in hypertension and aging. Gender Med 2008; 5 Suppl A: S46-64.
111. Florian M, Lu Y, Angle M, Magder S. Estrogen induced changes in Akt-dependent activation of endothelial nitric oxide synthase and vasodilation. Steroids 2004; 69: 637-45.
112. Chambliss KL, Shaul PW. Estrogen modulation of endothelial nitric oxide synthase. Endocrine reviews 2002; 23: 665-86.
113. Haynes MP, Li L, Sinha D, et al. Src kinase mediates phosphatidylinositol 3-kinase/Akt-dependent rapid endothelial nitric-oxide synthase activation by estrogen. J Biol Chem 2003; 278: 2118-23.
114. McNeill AM, Zhang C, Stanczyk FZ, Duckles SP, Krause DN. Estrogen increases endothelial nitric oxide synthase via estrogen receptors in rat cerebral blood vessels: effect preserved after concurrent treatment with medroxyprogesterone acetate or progesterone. Stroke; a J Cerebral Circ 2002; 33: 1685-91.
115. Stirone C, Chu Y, Sunday L, Duckles SP, Krause DN. 17 Betaestradiol increases endothelial nitric oxide synthase mRNA copy number in cerebral blood vessels: quantification by real-time polymerase chain reaction. Eur J Pharmacol 2003; 478: 35-8.
116. Darblade B, Pendaries C, Krust A, et al. Estradiol alters nitric oxide production in the mouse aorta through the alpha-, but not beta-, estrogen receptor. Circ Res 2002; 90: 413-9.
117. Huang A, Sun D, Koller A, Kaley G. 17beta-estradiol restores endothelial nitric oxide release to shear stress in arterioles of male hypertensive rats. Circulation 2000; 101: 94-100.
118. Novella S, Laguna-Fernandez A, Lazaro-Franco M, et al. Estradiol, acting through estrogen receptor alpha, restores dimethylarginine dimethylaminohydrolase activity and nitric oxide production in oxLDL-treated human arterial endothelial cells. Mol Cell Endocrinol 2013; 365: 11-6.
119. Bolad I, Delafontaine P. Endothelial dysfunction: its role in hypertensive coronary disease. Curr Opin Cardiol 2005; 20: 270-4.
120. Evangelista AM, Deschamps AM, Liu D, Raghavachari N, Murphy E. miR-222 contributes to sex-dimorphic cardiac eNOS expression via ets-1. Physiol Genom 2013; 45: 493-8.
121. Haas E, Bhattacharya I, Brailoiu E, et al. Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circ Res 2009; 104: 288-91.
122. Nuedling S, Kahlert S, Loebbert K, et al. 17 Beta-estradiol stimulates expression of endothelial and inducible NO synthase in rat myocardium in-vitro and in-vivo. Cardiovas Res 1999; 43: 666-74.
123. Wen Y, Yang S, Liu R, et al. Estrogen attenuates nuclear factorkappa B activation induced by transient cerebral ischemia. Brain Res 2004; 1008: 147-54.
124. Kauser K, Sonnenberg D, Diel P, Rubanyi GM. Effect of 17betaoestradiol on cytokine-induced nitric oxide production in rat isolated aorta. Br J Pharmacol 1998; 123: 1089-96.
125. Tamura K, Yamaguchi K, Kogo H. 17Beta-estradiol inhibits ovariectomy-induced expression of inducible nitric oxide synthase in rat aorta in vivo. Life Sci 2000; 66: PL 259-64.
126. Cignarella A, Bolego C, Pelosi V, et al. Distinct roles of estrogen receptor-alpha and beta in the modulation of vascular inducible nitric-oxide synthase in diabetes. J Pharmacol Exp Ther 2009; 328: 174-82.
127. Bundalo IL, Nielsen K, Bang O. Angle dependent Fiber bragg grating inscription in microstructured polymer optical fibers. Optics express 2015; 23: 3699-707.
128. Lembo G, Rockman HA, Hunter JJ, et al. Elevated blood pressure and enhanced myocardial contractility in mice with severe IGF-1 deficiency. J Clin Invest 1996; 98: 2648-55.
129. Oliveira CR, Meneguz-Moreno RA, Aguiar-Oliveira MH, Barreto-Filho JA. Emerging role of the GH/IGF-I on cardiometabolic control. Arq Bras Cardiol 2011; 97: 434-9.
130. Moelling K, Schad K, Bosse M, Zimmermann S, Schweneker M. Regulation of Raf-Akt Cross-talk. J Biol Chem 2002; 277: 31099-106.
131. Delafontaine P, Song YH, Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol 2004; 24: 435-44.
132. Isgaard J, Arcopinto M, Karason K, Cittadini A. GH and the cardiovascular system: an update on a topic at heart. Endocrine 2015; 48: 25-35.
133. Longobardi S, Cuocolo A, Merola B, et al. Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency. Clin Endocrinol 1998; 48: 137-43.
134. Galderisi M, Vitale G, Lupoli G, et al. Inverse association between free insulin-like growth factor-1 and isovolumic relaxation in arterial systemic hypertension. Hypertension 2001; 38: 840-5.
135. Kotsis V, Stabouli S, Karafillis I, Nilsson P. Early vascular aging and the role of central blood pressure. J Hypertens 2011; 29: 1847-53.
136. Standley PR, Zhang F, Ram JL, Zemel MB, Sowers JR. Insulin attenuates vasopressin-induced calcium transients and a voltagedependent calcium response in rat vascular smooth muscle cells. J Clin Invest 1991; 88: 1230-6.
137. Hongo K, Nakagomi T, Kassell NF, et al. Effects of aging and hypertension on endothelium-dependent vascular relaxation in rat carotid artery. Stroke 1988; 19: 892-7.
138. Tivesten A, Bollano E, Andersson I, et al. Liver-derived insulinlike growth factor-I is involved in the regulation of blood pressure in mice. Endocrinology 2002; 143: 4235-42.
139. Vecchione C, Colella S, Fratta L, et al. Impaired insulin-like growth factor I vasorelaxant effects in hypertension. Hypertension 2001; 37: 1480-5.
140. Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int 1994; 45: 598-4.
141. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 1996; 98: 894-8.
142. Duerrschmidt N, Wippich N, Goettsch W, Broemme HJ, Morawietz H. Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem Biophys Res Commun 2000; 269: 713-7.
143. Li L, Fink G D, Watts S W, et al. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in lowrenin hypertension. Circulation 2003; 107: 1053-8.
144. Wedgwood S, McMullan DM, Bekker JM, Fineman JR, Black SM. Role for endothelin-1-induced superoxide and peroxynitrite production in rebound pulmonary hypertension associated with inhaled nitric oxide therapy. Circ Res 2001; 89: 357-64.
145. Backer JM, Myers MG, Shoelson SE, et al. Phosphatidylinositol 3’-kinase is activated by association with IRS-1 during insulin stimulation. The EMBO Journal 1992; 11: 3469-79.
146. Somwar R, Sumitani S, Taha C, Sweeney G, Klip A. Temporal activation of p70 S6 kinase and Akt1 by insulin: PI 3-kinasedependent and-independent mechanisms. Am J Physiol 1998; 275: E618-25.
147. Zeng G, Nystrom FH, Ravichandran LV, et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000; 101: 1539-45.
148. Isenovic E, Muniyappa R, Milivojevic N, Rao Y, Sowers JR. Role of PI3-kinase in isoproterenol and IGF-1 induced ecNOS activity. Biochem Biophys Res Commun 2001; 285: 954-8.
149. Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res 2011; 21: 103-15.
150. Cittadini A, Monti MG, Castiello MC, et al. Insulin-like growth factor-1 protects from vascular stenosis and accelerates reendothelialization in a rat model of carotid artery injury. J Thrombosis Haemostasis 2009; 7: 1920-8.
151. Stokoe D, Stephens LR, Copeland T, et al. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 1997; 277: 567-70.
152. Elzaouk L, Leimbacher W, Turri M, et al. Dwarfism and low insulin-like growth factor-1 due to dopamine depletion in Pts-/-mice rescued by feeding neurotransmitter precursors and H4-biopterin. J Biol Chem 2003; 278: 28303-11.
153. Tanaka J, Koshimura K, Murakami Y, Kato Y. Possible involvement of tetrahydrobiopterin in the trophic effect of insulin-like growth factor-1 on rat pheochromocytoma-12 (PC12) cells. Neurosci Lett 2002; 328: 201-3.
154. Melnyk NC, Lister AL, Van Der Kraak GJ. Regulation of ovarian prostaglandin synthesis in the zebrafish: actions of 17a, 20-dihydroxy-4-pregnen-3-one and insulin-like growth factor-1. Frontiers in Endocrinology.
155. Gorin Y, Kim NH, Feliers D, et al. Angiotensin II activates Akt/protein kinase B by an arachidonic acid/redox-dependent pathway and independent of phosphoinositide 3-kinase. FASEB J 2001; 15: 1909-20.
156. Jin C, Guo J, Qiu X, et al. IGF-1 induces iNOS expression via the p38 MAPK signal pathway in the anti-apoptotic process in pulmonary artery smooth muscle cells during PAH. J Recept Signal Transduct Res 2014; 34: 325-31.